Expression profiling of clonal lymphocyte cell cultures from Rett syndrome patients

Ivan J. Delgado, Dong Sun Kim, Karen N. Thatcher, Janine M LaSalle, Ignantia B. Van den Veyver

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: More than 85% of Rett syndrome (RTT) patients have heterozygous mutations in the X-linked MECP2 gene which encodes methyl-CpG-binding protein 2, a transcriptional repressor that binds methylated CpG sites. Because MECP2 is subject to X chromosome inactivation (XCI), girls with RTT express either the wild type or mutant MECP2 in each of their cells. To test the hypothesis that MECP2 mutations result in genome-wide transcriptional deregulation and identify its target genes in a system that circumvents the functional mosaicism resulting from XCI, we performed gene expression profiling of pure populations of untransformed T-lymphocytes that express either a mutant or a wild-type allele. Methods: Single T lymphocytes from a patient with a c.473C>T (p.T158M) mutation and one with a c.1308-1309delTC mutation were subcloned and subjected to short term culture. Gene expression profiles of wild-type and mutant clones were compared by oligonucleotide expression microarray analysis. Results: Expression profiling yielded 44 upregulated genes and 77 downregulated genes. We compared this gene list with expression profiles of independent microarray experiments in cells and tissues of RTT patients and mouse models with Mecp2 mutations. These comparisons identified a candidate MeCP2 target gene, SPOCKI, downregulated in two independent microarray experiments, but its expression was not altered by quantitative RT-PCR analysis on brain tissues from a RTT mouse model. Conclusion: Initial expression profiling from T-cell clones of RTT patients identified a list of potential MeCP2 target genes. Further detailed analysis and comparison to independent microarray experiments did not confirm significantly altered expression of most candidate genes. These results are consistent with other reported data.

Original languageEnglish (US)
Article number61
JournalBMC Medical Genetics
Volume7
DOIs
StatePublished - Jul 21 2006

Fingerprint

Rett Syndrome
Cell Culture Techniques
Lymphocytes
Genes
Mutation
X Chromosome Inactivation
T-Lymphocytes
Down-Regulation
Clone Cells
Methyl-CpG-Binding Protein 2
X-Linked Genes
Mosaicism
Gene Expression Profiling
Microarray Analysis
Oligonucleotide Array Sequence Analysis
Transcriptome
Alleles
Genome
Polymerase Chain Reaction
Brain

ASJC Scopus subject areas

  • Medicine(all)
  • Genetics(clinical)

Cite this

Expression profiling of clonal lymphocyte cell cultures from Rett syndrome patients. / Delgado, Ivan J.; Kim, Dong Sun; Thatcher, Karen N.; LaSalle, Janine M; Van den Veyver, Ignantia B.

In: BMC Medical Genetics, Vol. 7, 61, 21.07.2006.

Research output: Contribution to journalArticle

Delgado, Ivan J. ; Kim, Dong Sun ; Thatcher, Karen N. ; LaSalle, Janine M ; Van den Veyver, Ignantia B. / Expression profiling of clonal lymphocyte cell cultures from Rett syndrome patients. In: BMC Medical Genetics. 2006 ; Vol. 7.
@article{570175d0a9d147b7ad39a868fbff30a4,
title = "Expression profiling of clonal lymphocyte cell cultures from Rett syndrome patients",
abstract = "Background: More than 85{\%} of Rett syndrome (RTT) patients have heterozygous mutations in the X-linked MECP2 gene which encodes methyl-CpG-binding protein 2, a transcriptional repressor that binds methylated CpG sites. Because MECP2 is subject to X chromosome inactivation (XCI), girls with RTT express either the wild type or mutant MECP2 in each of their cells. To test the hypothesis that MECP2 mutations result in genome-wide transcriptional deregulation and identify its target genes in a system that circumvents the functional mosaicism resulting from XCI, we performed gene expression profiling of pure populations of untransformed T-lymphocytes that express either a mutant or a wild-type allele. Methods: Single T lymphocytes from a patient with a c.473C>T (p.T158M) mutation and one with a c.1308-1309delTC mutation were subcloned and subjected to short term culture. Gene expression profiles of wild-type and mutant clones were compared by oligonucleotide expression microarray analysis. Results: Expression profiling yielded 44 upregulated genes and 77 downregulated genes. We compared this gene list with expression profiles of independent microarray experiments in cells and tissues of RTT patients and mouse models with Mecp2 mutations. These comparisons identified a candidate MeCP2 target gene, SPOCKI, downregulated in two independent microarray experiments, but its expression was not altered by quantitative RT-PCR analysis on brain tissues from a RTT mouse model. Conclusion: Initial expression profiling from T-cell clones of RTT patients identified a list of potential MeCP2 target genes. Further detailed analysis and comparison to independent microarray experiments did not confirm significantly altered expression of most candidate genes. These results are consistent with other reported data.",
author = "Delgado, {Ivan J.} and Kim, {Dong Sun} and Thatcher, {Karen N.} and LaSalle, {Janine M} and {Van den Veyver}, {Ignantia B.}",
year = "2006",
month = "7",
day = "21",
doi = "10.1186/1471-2350-7-61",
language = "English (US)",
volume = "7",
journal = "BMC Medical Genetics",
issn = "1471-2350",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Expression profiling of clonal lymphocyte cell cultures from Rett syndrome patients

AU - Delgado, Ivan J.

AU - Kim, Dong Sun

AU - Thatcher, Karen N.

AU - LaSalle, Janine M

AU - Van den Veyver, Ignantia B.

PY - 2006/7/21

Y1 - 2006/7/21

N2 - Background: More than 85% of Rett syndrome (RTT) patients have heterozygous mutations in the X-linked MECP2 gene which encodes methyl-CpG-binding protein 2, a transcriptional repressor that binds methylated CpG sites. Because MECP2 is subject to X chromosome inactivation (XCI), girls with RTT express either the wild type or mutant MECP2 in each of their cells. To test the hypothesis that MECP2 mutations result in genome-wide transcriptional deregulation and identify its target genes in a system that circumvents the functional mosaicism resulting from XCI, we performed gene expression profiling of pure populations of untransformed T-lymphocytes that express either a mutant or a wild-type allele. Methods: Single T lymphocytes from a patient with a c.473C>T (p.T158M) mutation and one with a c.1308-1309delTC mutation were subcloned and subjected to short term culture. Gene expression profiles of wild-type and mutant clones were compared by oligonucleotide expression microarray analysis. Results: Expression profiling yielded 44 upregulated genes and 77 downregulated genes. We compared this gene list with expression profiles of independent microarray experiments in cells and tissues of RTT patients and mouse models with Mecp2 mutations. These comparisons identified a candidate MeCP2 target gene, SPOCKI, downregulated in two independent microarray experiments, but its expression was not altered by quantitative RT-PCR analysis on brain tissues from a RTT mouse model. Conclusion: Initial expression profiling from T-cell clones of RTT patients identified a list of potential MeCP2 target genes. Further detailed analysis and comparison to independent microarray experiments did not confirm significantly altered expression of most candidate genes. These results are consistent with other reported data.

AB - Background: More than 85% of Rett syndrome (RTT) patients have heterozygous mutations in the X-linked MECP2 gene which encodes methyl-CpG-binding protein 2, a transcriptional repressor that binds methylated CpG sites. Because MECP2 is subject to X chromosome inactivation (XCI), girls with RTT express either the wild type or mutant MECP2 in each of their cells. To test the hypothesis that MECP2 mutations result in genome-wide transcriptional deregulation and identify its target genes in a system that circumvents the functional mosaicism resulting from XCI, we performed gene expression profiling of pure populations of untransformed T-lymphocytes that express either a mutant or a wild-type allele. Methods: Single T lymphocytes from a patient with a c.473C>T (p.T158M) mutation and one with a c.1308-1309delTC mutation were subcloned and subjected to short term culture. Gene expression profiles of wild-type and mutant clones were compared by oligonucleotide expression microarray analysis. Results: Expression profiling yielded 44 upregulated genes and 77 downregulated genes. We compared this gene list with expression profiles of independent microarray experiments in cells and tissues of RTT patients and mouse models with Mecp2 mutations. These comparisons identified a candidate MeCP2 target gene, SPOCKI, downregulated in two independent microarray experiments, but its expression was not altered by quantitative RT-PCR analysis on brain tissues from a RTT mouse model. Conclusion: Initial expression profiling from T-cell clones of RTT patients identified a list of potential MeCP2 target genes. Further detailed analysis and comparison to independent microarray experiments did not confirm significantly altered expression of most candidate genes. These results are consistent with other reported data.

UR - http://www.scopus.com/inward/record.url?scp=33748892622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748892622&partnerID=8YFLogxK

U2 - 10.1186/1471-2350-7-61

DO - 10.1186/1471-2350-7-61

M3 - Article

C2 - 16859563

AN - SCOPUS:33748892622

VL - 7

JO - BMC Medical Genetics

JF - BMC Medical Genetics

SN - 1471-2350

M1 - 61

ER -